Alzheimer's & Cognition
From the Journals
Can 6 minutes of intense cycling put the brakes on Alzheimer’s?
Six minutes of high-intensity cycling increased circulating levels of brain-derived neurotrophic factor to a significantly greater extent than...
Livin' on the MDedge
Early retirement and the terrible, horrible, no good, very bad cognitive decline
Plus: The ancient origins of smallpox and the medical world’s newest additions to an inventive hall of fame.
From the Journals
Some BP meds tied to significantly lower risk for dementia, Alzheimer’s
Antihypertensive medications that stimulate type 2 and 4 angiotensin II receptors may reduce the rate of dementia compared with those that inhibit...
From the Journals
Hearing loss strongly tied to increased dementia risk
Even mild hearing loss was associated with increased dementia risk.
Commentary
Age competency exams for physicians – yes or no?
Almost one-third of licensed doctors in the United States were 60 years of age or older, according to a survey conducted in 2020.
FDA/CDC
What to know about newly approved Alzheimer’s drug
The drug has shown moderate positive effects in clinical trials in slowing early...
FDA/CDC
FDA approves second antiamyloid for Alzheimer’s disease
Like its controversial cousin aducanumab, lecanemab was approved under the FDA’s accelerated approval pathway.
FDA/CDC
FDA considers regulating CBD products
The products can have drug-like effects on the body and contain CBD (cannabidiol) and THC (tetrahydrocannabinol).
From the Journals
Strong link between muscle strength, mobility, and brain health
“The implication is that muscular strength and mobility influence brain health.”
News from the FDA/CDC
Alzheimer’s Association to CMS: Ditch restraints on amyloid drugs
The CMS coverage restrictions for anti-amyloid drugs were finalized in April on the...
Conference Coverage
Antipsychotic shows benefit for Alzheimer’s agitation
Currently, there’s no Food and Drug Administration–approved treatment for agitation in AD.